Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer.
Y. R. Miao, K. N. Thakkar, J. Qian, M. S. Kariolis, W. Huang, S. A. Nandagopal, T. Yang, A. N. Diep, G. M. Cherf, Y. Xu, E. J. Moon, Y. Xiao, H. Alemany, T. Li, W. Yu, , A. J. Giaccia
The paper develops a high-affinity sPD-1 decoy molecule that neutralizes both PD-L1 and PD-L2, showing superior antitumor activity in ovarian cancer models compared to PD-1/PD-L1 antibodies.
bioRxiv · Jan 19, 2020 · PreprintCancer Biology